surmount-1 trial tirzepatide non-diabetic obesity weight loss once weekly for the treatment of in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 Tirzepatide for maintenance of bodyweight
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
00656-2/asset/09a3e122-d7af-44ed-abbd-db334fe4ca36/main.assets/gr3.jpg)


























